{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:16:27Z","timestamp":1787159787657,"version":"build-2736575974"},"reference-count":239,"publisher":"Korean Association of Internal Medicine","issue":"3","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["kjim.org"],"crossmark-restriction":true},"short-container-title":["Korean J Intern Med"],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:p>Follicular lymphoma (FL) is the most common type of indolent lymphoma, and the prognosis is favorable for most patients. However, FL remains generally incurable, and relapse is common. Patients are at risk of developing treatment-resistant lymphoma, particularly when early disease progression occurs or transformation to aggressive lymphoma takes place. Furthermore, lymphoma is the leading cause of death among patients with FL, emphasizing the need for more effective treatment strategies. This review summarizes therapeutic approaches for FL, with a focus on therapies currently in development. Recent biological insights have driven the emergence of highly effective treatments, including novel immune and targeted therapies. Clinical trials are assessing the efficacy of these novel approaches, which are increasingly used in earlier line settings. In the future, FL therapy is expected to rely less on chemotherapeutic methods, extend remission, and potentially enable cures for a growing number of patients.<\/jats:p>","DOI":"10.3904\/kjim.2024.279","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:33:04Z","timestamp":1740105184000},"page":"371-393","update-policy":"https:\/\/doi.org\/10.3904\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Follicular lymphoma: contemporary clinical management with a focus on recent therapeutic advances"],"prefix":"10.3904","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0287-7124","authenticated-orcid":true,"given":"Robert","family":"Kridel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2270","reference":[{"key":"ref1","volume-title":"","year":"c2024"},{"key":"ref2","first-page":"717","volume-title":"Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin\u2019s Lymphoma Classification Project","author":"Anderson","year":"1998"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.00400"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.885513"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.59.7534"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000258"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010263"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.65.7163"},{"key":"ref9","first-page":"1720","volume-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","author":"Alaggio","year":"2022"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1126\/science.6093263"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.330"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2014.06.019"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-799080"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.9.3376"},{"key":"ref15","first-page":"333","volume-title":"Follicular lymphomas in children and young adults: a comparison of the pediatric variant with usual follicular lymphoma","author":"Liu","year":"2013"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-429514"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.01980.x"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2017.10.006"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17383"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/ng.518"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/nature09730"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-500264"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-10-2460"},{"key":"ref24","first-page":"183","volume-title":"Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma","author":"Okosun","year":"2016"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1172\/jci98288"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01111-w"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010779"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-154013"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00169-2"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009467"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0043-y"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009855"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0181-4"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34408-0"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-862292"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.05.011"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024496"},{"key":"ref38","first-page":"2159","volume-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","author":"Dave","year":"2004"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1172\/jci63186"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.bcd-21-0075"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.02365"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-18-1090"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1501199112"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.21.3991"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-816405"},{"key":"ref47","first-page":"1503","volume-title":"Follicular Lymphoma Evaluation Index (FLEX): a new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy","author":"Mir","year":"2020"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.66.9440"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(14)70008-0"},{"key":"ref50","first-page":"1530","volume-title":"Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial","author":"Trotman","year":"2018"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30102-5"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.209031"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008119"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016000786"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14201"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.165415"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.32"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130208"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-691345"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.8800"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25149"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.09.051"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1996.14.4.1282"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(01)01747-3"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.08.010"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.40.6546"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131158"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29491"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-843540"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.05.013"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30686-0"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004939"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06545.x"},{"key":"ref74","first-page":"e160","volume-title":"Rituximab with involved field irradiation for early-stage nodal follicular lymphoma: results of the MIR study","author":"Herfarth","year":"2018"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.990010"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.77.9892"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(03)14110-4"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1997.15.3.1110"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70027-0"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.56.5853"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02327"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.13.5376"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.082412"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61763-2"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.00605"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(10)62175-7"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01073"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.74.1652"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15720"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01234"},{"key":"ref93","first-page":"655","volume-title":"Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment na\u00efve advanced-stage follicular lymphoma: a subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi","author":"Nizzoli","year":"2023"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1614598"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.209015"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.8960"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19166"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100549"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285219"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx496"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879643"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70455-3"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1805104"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00843"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013526"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33660"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33659"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1786554"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4588"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15149"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15708"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00340-z"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.281421"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(22)00033-3"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000745"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00447-7"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30097-3"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.3656"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.01.021"},{"key":"ref120","first-page":"301","volume-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","author":"Kr\u00f6nke","year":"2014"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244917"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1126\/science.1177319"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-05-0577"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06841.x"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-217687"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21468"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.59.9258"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-2221"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12755"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00010"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158631"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000847492.88194.df"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(19)30089-4"},{"key":"ref134","first-page":"P1132","volume-title":"Safety and efficacy of golcadomide, a potential first-in-class celmod agent \u00b1 rituximab in a phase 1\/2 open-label study of patients with relapsed\/refractory (R\/R) follicular lymphoma (FL)","author":"Chavez","year":"2024"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v94.10.3325.422k13_3325_3333"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.09.8327"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.10.023"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.03.022"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.030320"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18640"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.12.771"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31374"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31264"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535443"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-421826"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.1"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.65.9789"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004753"},{"key":"ref149","first-page":"4055","volume-title":"PD-1 blockade with pembrolizumab in relapsed low grade non-hodgkin lymphoma","author":"Ding","year":"2017"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006240"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.12.010"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00539-8"},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03847-5"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931"},{"key":"ref155","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01467"},{"key":"ref156","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000905"},{"key":"ref157","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1708566"},{"key":"ref158","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00591-x"},{"key":"ref159","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021243"},{"key":"ref160","first-page":"325","volume-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","author":"Fowler","year":"2022"},{"key":"ref161","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021567"},{"key":"ref162","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02986-9"},{"key":"ref163","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000967804.31464.ce"},{"key":"ref164","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-184653"},{"key":"ref165","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008150"},{"key":"ref166","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178629"},{"key":"ref167","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00931"},{"key":"ref168","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00335-7"},{"key":"ref169","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02329"},{"key":"ref170","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03175"},{"key":"ref171","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00889-8"},{"key":"ref172","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(24)00166-2"},{"key":"ref173","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(22)00072-2"},{"key":"ref174","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2239"},{"key":"ref175","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012916"},{"key":"ref176","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283737"},{"key":"ref177","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2023.2262066"},{"key":"ref178","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.07.044"},{"key":"ref179","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1807315"},{"key":"ref180","doi-asserted-by":"publisher","DOI":"10.1002\/hon.57_2629"},{"key":"ref181","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153683"},{"key":"ref182","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.04.011"},{"key":"ref183","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30145-1"},{"key":"ref184","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30441-1"},{"key":"ref185","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147751"},{"key":"ref186","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47701-x"},{"key":"ref187","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179910"},{"key":"ref188","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-190610"},{"key":"ref189","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182440"},{"key":"ref190","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.32.1398"},{"key":"ref191","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283002"},{"key":"ref192","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.117473"},{"key":"ref193","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12819"},{"key":"ref194","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14698"},{"key":"ref195","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.154377"},{"key":"ref196","first-page":"370","volume-title":"KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas","author":"Heward","year":"2021"},{"key":"ref197","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.209"},{"key":"ref198","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-003921"},{"key":"ref199","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1002057107"},{"key":"ref200","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718494"},{"key":"ref201","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-640912"},{"key":"ref202","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-640805"},{"key":"ref203","first-page":"57","volume-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","author":"Pal Singh","year":"2018"},{"key":"ref204","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236471"},{"key":"ref205","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15552"},{"key":"ref206","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-1047"},{"key":"ref207","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-3239"},{"key":"ref208","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282401"},{"key":"ref209","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.8853"},{"key":"ref210","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-804641"},{"key":"ref211","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010298"},{"key":"ref212","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.36.15_suppl.7549"},{"key":"ref213","volume-title":"Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003)","author":"Strati","year":"2024"},{"key":"ref214","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002183"},{"key":"ref215","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00775"},{"key":"ref216","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-3741"},{"key":"ref217","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1400029"},{"key":"ref218","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1314583"},{"key":"ref219","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.75.4648"},{"key":"ref220","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.00915"},{"key":"ref221","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19419"},{"key":"ref222","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01798-0"},{"key":"ref223","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.08.022"},{"key":"ref224","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19456"},{"key":"ref225","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.70.4320"},{"key":"ref226","first-page":"2628","volume-title":"Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed\/refractory follicular lymphoma","author":"Zinzani","year":"2020"},{"key":"ref227","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.29.2813"},{"key":"ref228","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24671"},{"key":"ref229","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-019-0098-8"},{"key":"ref230","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19671"},{"key":"ref231","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy056"},{"key":"ref232","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(19)30026-2"},{"key":"ref233","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(21)00311-2"},{"key":"ref234","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.36.15_suppl.7507"},{"key":"ref235","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007512"},{"key":"ref236","first-page":"229","volume-title":"Impact of therapy and disease-related symptoms on health-related quality of life in patients with follicular lymphoma: results of the population-based PHAROS-registry","author":"Oerlemans","year":"2014"},{"key":"ref237","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02882-1"},{"key":"ref238","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm543"},{"key":"ref239","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.14425"}],"container-title":["The Korean Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/kjim.org\/upload\/kjim-2024-279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/kjim.org\/journal\/view.php?doi=10.3904\/kjim.2024.279","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/kjim.org\/upload\/kjim-2024-279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:29:32Z","timestamp":1746750572000},"score":1,"resource":{"primary":{"URL":"http:\/\/kjim.org\/journal\/view.php?doi=10.3904\/kjim.2024.279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":239,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"URL":"https:\/\/doi.org\/10.3904\/kjim.2024.279","relation":{},"ISSN":["1226-3303","2005-6648"],"issn-type":[{"value":"1226-3303","type":"print"},{"value":"2005-6648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"assertion":[{"value":"2024-08-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-21","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}